April 22, 2022
Vaxine is pleased to see its latest Covid-19 vaccine Phase 2 trial results complete peer review and be published in the journal “Clinical Microbiology and Infection”, the official journal of the European Society of Clinical Microbiology and Infectious Diseases.
This paper investigates the immunogenicity ad efficacy of Vaxine’s vaccine composed of a recombinant prefusion-stabilized SARS-CoV-2 spike protein combined with Advax-CpG55.2™adjuvant, in seronegative and seropositive populations as primary vaccination.
Link to the published paper:
- Click to share on Facebook (Opens in new window)
- Click to share on Twitter (Opens in new window)
- Click to share on Telegram (Opens in new window)
- Click to share on LinkedIn (Opens in new window)
- Click to share on Reddit (Opens in new window)
- Click to share on WhatsApp (Opens in new window)
- Click to share on Tumblr (Opens in new window)
- Click to share on Pinterest (Opens in new window)
- Click to share on Pocket (Opens in new window)
- Click to email a link to a friend (Opens in new window)
- Click to print (Opens in new window)
